After seeing its stock price slide 10 percent at the beginning of the week after the FDA requested more information on its lung treatment Surfaxin, Discovery Labs announced today that it will respond to the agency's request in October. But executives at the company emphasized that the dozen points the FDA wants clarified deal with chemistry and manufacturing issues, not the results of the clinical trials used to obtain an "approvable" letter.
- read this AP story for more